These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10355003)

  • 21. Guidelines for early treatment trials in patients presenting with clinical and paraclinical abnormalities which put them at high risk for conversion to multiple sclerosis. European Charcot Foundation Working Group for Treatment Trials.
    Mult Scler; 1995; 1 Suppl 1():S55-9. PubMed ID: 9345401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.
    Webb UH
    J Neurosci Nurs; 2008 Dec; 40(6):356-61. PubMed ID: 19170303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seeing injectable MS therapies differently: they are more similar than different.
    Fox RJ; Arnold DL
    Neurology; 2009 Jun; 72(23):1972-3. PubMed ID: 19439722
    [No Abstract]   [Full Text] [Related]  

  • 24. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
    Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
    Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
    Cristiano E
    Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic resonance imaging as an outcome measure in the treatment of multiple sclerosis: results of the interferon beta trial.
    Koopmans RA; Paty DW
    Mult Scler; 1995; 1 Suppl 1():S22-3. PubMed ID: 9345393
    [No Abstract]   [Full Text] [Related]  

  • 27. Repeated intervals of high-dose corticosteroid: an overlooked therapy in multiple sclerosis.
    Johnson LN; Morey SS
    Mo Med; 2005; 102(1):47-50. PubMed ID: 15754617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.
    Francis GS; Rice GP; Alsop JC;
    Neurology; 2005 Jul; 65(1):48-55. PubMed ID: 16009884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The management of multiple sclerosis in children: a European view.
    Ghezzi A; Banwell B; Boyko A; Amato MP; Anlar B; Blinkenberg M; Boon M; Filippi M; Jozwiak S; Ketelslegers I; Kornek B; Lim M; Lindstrom E; Nadj C; Neuteboom R; Rocca MA; Rostasy K; Tardieu M; Wassmer E; Catsman-Berrevoets C; Hintzen R
    Mult Scler; 2010 Oct; 16(10):1258-67. PubMed ID: 20685764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
    Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.
    Ytterberg C; Johansson S; Andersson M; Olsson D; Link H; Holmqvist LW; von Koch L
    Acta Neurol Scand; 2007 Aug; 116(2):96-9. PubMed ID: 17661794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Disease-modifying treatment of MS--progress with complications].
    Fagius J
    Lakartidningen; 2003 Mar; 100(13):1164, 1167-8. PubMed ID: 12705166
    [No Abstract]   [Full Text] [Related]  

  • 36. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL;
    Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple sclerosis update.
    Mayr WT; Rodriguez M
    Minn Med; 2002 Jun; 85(6):36-9. PubMed ID: 12092437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Preventive immunotherapy].
    Boquete M; Carballada F; Expósito F; González A
    Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Future immunotherapies in multiple sclerosis.
    Blevins G; Martin R
    Semin Neurol; 2003 Jun; 23(2):147-58. PubMed ID: 12894380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.